Evotec’s Turnaround Math Gets Harder as Half-Year Losses Deepen

The numbers landing on Evotec’s desk last Thursday left little room for spin. Germany’s largest independent drug discovery contractor posted first-half revenue of €300.1 million, down 19.2 percent from the prior-year period, while adjusted EBITDA swung to a loss of €42.7 million — a sharp deterioration from the €1.9 million deficit recorded a year earlier. […] The post Evotec’s Turnaround Math…